Last updated: September 6, 2026
Cocaine hydrochloride is a small, highly specialized pharmaceutical market centered on FDA-approved nasal solutions used for local anesthesia during diagnostic and surgical procedures of the nasal cavities. The U.S. market has two branded products, Goprelto and Numbrino, but neither sponsor publicly reports standalone product revenue. Commercial growth is constrained by narrow procedural use, Schedule II controls, hospital purchasing requirements, and competition from lower-cost local anesthetics.
What pharmaceutical cocaine hydrochloride products are FDA approved?
The FDA-approved pharmaceutical market is limited to intranasal cocaine hydrochloride products. These products are not approved for recreational use, systemic pain treatment, or treatment of cocaine-use disorder.
| Product |
Active ingredient |
Dosage form |
FDA approval |
Primary use |
Commercial company |
| Goprelto |
Cocaine hydrochloride |
4% nasal solution |
2017 |
Induction of local anesthesia of nasal mucosa in adults |
Noden Pharma |
| Numbrino |
Cocaine hydrochloride |
4% nasal solution |
2020 |
Induction of local anesthesia of nasal mucosa in adults |
Nexus Pharmaceuticals |
Goprelto was approved under NDA 209521 in December 2017. Numbrino was approved in January 2020 under a separate NDA. Both products contain 40 mg of cocaine hydrochloride per mL and are administered intranasally in controlled procedural settings. [1,2]
The approved market is therefore a procedural-anesthesia niche rather than a broad pharmaceutical category. Demand is linked to the number of eligible nasal diagnostic and surgical procedures, physician preference, institutional formularies, and the availability of alternative anesthetic protocols.
How large is the cocaine hydrochloride pharmaceutical market?
No audited public source establishes a reliable global or U.S. market-size figure for pharmaceutical cocaine hydrochloride. Product sponsors are privately held or do not disclose brand-level revenue, and the products are not reported as separate public-company operating segments.
The commercial market is likely small relative to standard local anesthetics because:
- The labeled patient population is limited to adults undergoing nasal procedures.
- Treatment is administered in procedural settings rather than through chronic outpatient prescriptions.
- Many institutions can use lidocaine, topical tetracaine, oxymetazoline combinations, or other local-anesthetic protocols.
- Cocaine hydrochloride requires Schedule II controls and specialized inventory procedures.
- Hospitals and ambulatory surgery centers may require pharmacy, compliance, and diversion-control review before formulary adoption.
- The drug is generally used as a single-procedure product, limiting refill and recurring-prescription economics.
The relevant commercial denominator is not the total number of ENT procedures. It is the subset of nasal procedures in which a clinician considers cocaine hydrochloride clinically preferable to alternative topical anesthetic and vasoconstrictor regimens.
What drives demand for pharmaceutical cocaine hydrochloride?
Cocaine hydrochloride has two pharmacologic attributes that support its use in nasal procedures: local anesthesia and vasoconstriction. That combination can simplify procedural preparation and reduce bleeding in selected cases.
Demand is concentrated in:
- Otolaryngology offices
- Hospital operating rooms
- Ambulatory surgery centers
- Nasal endoscopy and diagnostic procedure suites
- Academic medical centers with established ENT protocols
The strongest commercial use case is a setting in which clinicians value a single product with both anesthetic and vasoconstrictive effects. The commercial disadvantage is that many institutions already have established protocols using separate products, particularly lidocaine and oxymetazoline.
Purchasing decisions are therefore influenced by total procedural workflow, not only by the acquisition price of the vial. A product may gain formulary support if it reduces preparation steps, improves clinician familiarity, or fits an existing controlled-substance process. It may lose share if pharmacy departments prioritize lower acquisition cost or avoid Schedule II inventory.
How does cocaine hydrochloride compare with alternative local anesthetics?
Cocaine hydrochloride competes against both combination topical regimens and conventional local anesthetics.
| Attribute |
Cocaine hydrochloride nasal solution |
Lidocaine-based regimen |
Tetracaine-based regimen |
| Local anesthesia |
Yes |
Yes |
Yes |
| Vasoconstrictive effect |
Yes |
Usually requires separate vasoconstrictor |
Usually requires separate vasoconstrictor |
| Controlled substance |
Schedule II |
Generally not Schedule II |
Generally not Schedule II |
| Procedural setting |
Primarily nasal procedures |
Broad procedural use |
Broad topical use |
| Inventory burden |
High |
Lower |
Lower |
| Reimbursement leverage |
Limited and procedure-dependent |
Established |
Established |
| Main commercial risk |
Substitution and compliance burden |
Lower cost and broad availability |
Lower cost and broad availability |
Cocaine hydrochloride's principal differentiation is functional rather than molecular novelty. It combines topical anesthesia with vasoconstriction, but that benefit must offset higher compliance requirements and the availability of alternative products.
What is the FDA regulatory status of Goprelto and Numbrino?
Both Goprelto and Numbrino are FDA-approved prescription products containing Schedule II cocaine hydrochloride. Their labeling limits use to adults and to induction of local anesthesia of mucous membranes during diagnostic and surgical procedures involving the nasal cavities. [1,2]
The products are not approved for:
- Chronic pain
- General anesthesia
- Treatment of nasal congestion
- Treatment of cocaine dependence
- Psychiatric or neurologic indications
- Pediatric routine use
FDA approval does not eliminate the commercial effect of controlled-substance regulation. Manufacturers, wholesalers, pharmacies, hospitals, and surgical centers must maintain appropriate ordering, storage, recordkeeping, and diversion controls under the federal Controlled Substances Act and applicable state law. [3]
The market also has limited expansion potential from label growth. A new indication would require clinical development and FDA review. Off-label use may occur, but it does not provide the same reimbursement, formulary, or commercial support as an approved indication.
What patents protect pharmaceutical cocaine hydrochloride?
Patent protection is product-specific and must be assessed from the current FDA Orange Book, issued patents, terminal disclaimers, and any later patent litigation. The relevant protection may include:
- Formulation patents
- Nasal-delivery patents
- Concentration and excipient claims
- Manufacturing and stability claims
- Method-of-use claims for nasal procedures
- Device or packaging claims
Cocaine hydrochloride itself is an old active ingredient. The principal intellectual-property value therefore lies in the finished dosage form, delivery method, manufacturing process, and approved clinical use rather than in composition-of-matter protection for a new chemical entity.
The FDA Orange Book should be treated as the primary source for patents listed against approved products. The Orange Book can identify patents submitted by sponsors, but it does not determine whether those patents are valid or enforceable. Patent scope and enforceability require review of the patent files, prosecution history, claim construction, and any district-court or Patent Trial and Appeal Board proceedings. [4]
When does cocaine hydrochloride lose exclusivity?
Cocaine hydrochloride does not have the exclusivity profile of a new chemical entity. The active ingredient has long been known, so the five-year NCE exclusivity framework generally does not define the market timeline.
FDA exclusivity may instead arise from:
- Three-year exclusivity for qualifying clinical investigations supporting a new application or supplement
- Pediatric exclusivity, if granted
- Orphan-drug exclusivity, if the relevant indication qualifies
- Listed patents covering the formulation or method of use
Goprelto entered the market in 2017, and Numbrino followed in 2020. Any original FDA regulatory exclusivity periods would be substantially shorter than the potential life of issued formulation or method patents. Generic entry would depend on the absence or resolution of blocking patents, the FDA filing strategy, and the commercial attractiveness of the market.
Because the market is small, a generic applicant may face a different economic calculation than it would for a high-volume oral drug. Litigation costs, controlled-substance manufacturing requirements, limited annual demand, and hospital purchasing concentration can reduce the incentive to file an abbreviated new drug application even after regulatory exclusivity expires.
Are there Paragraph IV challenges to Goprelto or Numbrino?
A Paragraph IV challenge would require a generic applicant to certify that a listed patent is invalid, unenforceable, or not infringed. Publicly available FDA and court records do not establish a major, market-defining Paragraph IV campaign against these products comparable to the litigation surrounding high-revenue specialty drugs.
The absence of a prominent public challenge is commercially relevant. It may indicate one or more of the following:
- Limited generic revenue opportunity
- A relatively small addressable procedure base
- High controlled-substance compliance costs
- Patent claims that have not yet attracted a challenger
- A market in which hospitals can substitute other anesthetic regimens without waiting for generic entry
A Paragraph IV case would create a launch-risk assessment centered on listed patent expiration, the 30-month stay, possible settlement terms, and the economics of manufacturing a controlled nasal solution. The existence of a Paragraph IV filing alone would not establish that generic entry will occur on the applicant's proposed date.
What is the litigation and settlement status?
No widely reported settlement has reshaped the U.S. pharmaceutical cocaine hydrochloride market. The commercial risk is therefore driven more by substitution, procurement, and regulatory compliance than by a known industry-wide patent settlement structure.
Potential litigation issues include:
- Infringement claims against a generic nasal solution
- Challenges to formulation or stability patents
- Patent-term calculations
- Orange Book listing disputes
- Controlled-substance manufacturing and distribution compliance
- Product-liability claims relating to cardiovascular or central-nervous-system effects
The approved labels warn about serious risks associated with cocaine hydrochloride, including cardiovascular effects, blood-pressure elevation, seizures, and abuse or dependence potential. These risks increase the importance of controlled administration and institutional oversight. [1,2]
What is the financial trajectory for Goprelto and Numbrino?
The public financial record does not provide a verified standalone revenue series for either product. The available evidence supports a qualitative trajectory:
| Period |
Market development |
Financial implication |
| 2017 |
Goprelto approved |
Creation of a branded procedural market |
| 2018-2019 |
Early commercial adoption |
Dependence on ENT protocols and formulary placement |
| 2020 |
Numbrino approved |
Entry of a second branded product and greater channel competition |
| 2020-2022 |
COVID-19 disruption |
Pressure on elective procedures and hospital purchasing |
| 2022 onward |
Normalization of procedural volumes |
Recovery depends on institutional adoption and price discipline |
| Long term |
Potential generic or therapeutic substitution |
Revenue erosion risk without new indications or stronger formulation protection |
The market has limited capacity for conventional pharmaceutical revenue expansion. Revenue growth is more likely to come from:
- Higher procedure volumes
- Increased adoption by ENT practices
- Expanded hospital formularies
- Price increases
- Geographic distribution growth
- New delivery formats or approved indications
Volume expansion is constrained by the narrow label. Price expansion is constrained by hospital procurement and substitution. The result is a market with potentially attractive unit economics but limited total addressable revenue.
Which companies are challenging the market?
The competitive landscape is defined less by direct branded competition than by substitution.
Direct branded competitors
Goprelto and Numbrino are the principal FDA-approved branded cocaine hydrochloride nasal products. Their competition can involve:
- Wholesale acquisition price
- Contracting terms
- Availability and back-order history
- Package size
- Pharmacy handling requirements
- Physician familiarity
- Manufacturer support for institutional implementation
Indirect competitors
Indirect competitors include topical lidocaine, tetracaine, oxymetazoline, phenylephrine, and compounded or institution-specific nasal anesthesia protocols. These products may have lower acquisition cost and fewer controlled-substance requirements.
Generic competitors
Generic entry is commercially possible but not automatic. A generic manufacturer would need to address controlled-substance registration, manufacturing controls, product equivalence, supply-chain security, and a market that may not support large production scale.
How strong is the patent estate for pharmaceutical cocaine hydrochloride?
The patent estate is likely stronger around the finished product than around the active ingredient. Its practical strength depends on four factors:
- Whether claims cover a commercially necessary formulation rather than an optional feature.
- Whether the claims are listed in the Orange Book.
- Whether a generic can design around the claims while maintaining bioequivalence and product performance.
- Whether the remaining patent term justifies litigation or settlement.
The estate should be viewed as moderate in strategic value but limited in absolute market value. Even a defensible formulation patent may not generate large damages or settlement economics if the annual market is small and therapeutic substitution is easy.
What generic launch scenarios exist?
Three launch scenarios are commercially plausible:
No near-term generic launch
The market remains divided between branded products because the opportunity is too small to justify development and litigation expense.
At-risk generic launch
A generic company launches before final resolution of listed patent disputes. This could produce rapid price erosion but exposes the applicant to damages and injunctive risk.
Post-patent generic entry
A generic launches after relevant patents expire or are successfully challenged. Price erosion would likely be meaningful, but total market savings would depend on the number of procedures using cocaine hydrochloride rather than substitute anesthetics.
A generic would not necessarily capture the entire branded market. Some institutions may continue using branded products for supply assurance, physician familiarity, or contracting reasons, while others may switch rapidly based on acquisition price.
What geographic markets matter?
The United States is the primary identifiable commercial market because Goprelto and Numbrino are FDA-approved U.S. products. Geographic expansion is limited by:
- National controlled-substance rules
- Country-specific drug approvals
- Narcotics import and export controls
- Local procurement systems
- Reimbursement differences
- Limited demand for pharmaceutical cocaine outside specialized procedural markets
A company seeking international growth would need to establish a separate regulatory and controlled-substance strategy. U.S. approval does not create automatic access to European, Canadian, or Asian markets.
Key Takeaways
- Pharmaceutical cocaine hydrochloride is a small, specialized procedural-anesthesia market.
- Goprelto was approved in 2017; Numbrino was approved in 2020.
- Both products are 4% intranasal cocaine hydrochloride solutions for adult nasal procedures.
- No reliable public standalone revenue series is available for either brand.
- The principal commercial constraints are narrow clinical use, Schedule II controls, hospital procurement, and substitution by lidocaine- or tetracaine-based protocols.
- Intellectual-property value is concentrated in formulation, delivery, manufacturing, and method-of-use claims.
- Generic entry is possible but may be economically unattractive because of limited market size and controlled-substance requirements.
- Financial growth depends more on procedural adoption and formulary penetration than on broad patient expansion.
- The market has no established high-value patent-settlement structure comparable to major specialty pharmaceuticals.
FAQs About the Cocaine Hydrochloride Pharmaceutical Market
Is pharmaceutical cocaine hydrochloride the same as illicit cocaine?
The active chemical is cocaine hydrochloride, but pharmaceutical products are manufactured under FDA quality standards, prescribed for defined medical uses, and distributed through controlled channels. Illicit cocaine is not an approved pharmaceutical product.
Is cocaine hydrochloride a Schedule II drug?
Yes. Pharmaceutical cocaine hydrochloride is subject to Schedule II controlled-substance requirements, including security, recordkeeping, ordering, storage, and diversion controls. [3]
Can hospitals substitute lidocaine for cocaine hydrochloride?
In many procedures, clinicians may use alternative local-anesthetic protocols, but substitution depends on the clinical judgment of the treating physician, institutional policy, and the specific procedural requirements.
Does cocaine hydrochloride have orphan-drug exclusivity?
The approved nasal-anesthesia indications are not generally treated as orphan indications. The relevant exclusivity analysis depends on the specific FDA approval, regulatory designation, and applicable Orange Book records.
What would most improve the financial outlook for cocaine hydrochloride products?
The strongest commercial levers would be broader procedural adoption, new FDA-approved indications, improved delivery systems, reliable supply, and evidence showing operational or clinical advantages over lower-cost topical anesthetic regimens.
References
- U.S. Food and Drug Administration. (2017). Goprelto (cocaine hydrochloride) nasal solution prescribing information. FDA.
- U.S. Food and Drug Administration. (2020). Numbrino (cocaine hydrochloride) nasal solution prescribing information. FDA.
- U.S. Drug Enforcement Administration. (2023). Controlled substance schedules. U.S. Department of Justice.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
